Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
CMTA Adds Science Writer Kenneth Raymond to Team
…for patients and their families. The CMTA has invested $23.5 million in the search for a cure and its Strategy to Accelerate Research (STAR) brings world-renowned CMT researchers together with…
Type1_Research_Developments
CMTAUSA.ORG over, please Demyelinating CMT: Type 1, Type X and Type 4 Research Developments In a multipronged approach to identifying novel treatments for demyelinating CMT, the CMTA is pursuing several…
Type1_Research_Developments_6-2020
…● We supported Acceleron Pharmaceuticals’ efforts (since ended) to strengthen affected muscles in individuals with demyelinating CMT. DEMYELINATING CMT: TYPE 1, TYPE X AND TYPE 4 STAR RESEARCH DEVELOPMENTS ●…
CMTA Patient & Research Summit
NJ/NYC Focus Group with Acceleron Pharma
The goal of Patients as Partners in Research is to advance the work of our Strategy to Accelerate Research (STAR) and enroll the patient community in the critical work of…
Regenacy Pharmaceuticals Announces Collaboration with the CMTA to Advance Ricolinostat for the Treatment of Hereditary Neuropathy
…Neuropathy Clinics and Cutaneous Innervation Laboratory in the Department of Neurology at the University of Rochester, and a member of the STAR (Strategy to Accelerate Research) advisory board for the…
Invitae Announces Major Expansion of Its Neurology Test Offerings
…17 existing neurology panels based on new discoveries in genetics research. With this latest expansion of its test offerings, Invitae will be able to provide clinicians, patients, and payers with…
CMTA Lunch & Learn: Neuro-Toxic Medication List Update
07/13/2023 @ 12:00 pm – 1:00 pm – Please join us on July 13 at 12:00 p.m. Eastern Time to hear an update on the newly reviewed and revised CMT Neuro-toxic Medication List. The CMTA funded a grant awarded to Guido Cavaletti, MD at the University of Milano-Bicocca to review and update the current CMT neuro-toxic medication list. Dr. Cavaletti and colleague, Dr. […]
CMTAreportSummer2023spreads
…SUMMER 2023 RESEARCH CMT PATIENTS URGE FASTER CLINICAL TRIALS ……………………………………………….. 10 APPLIED THERAPEUTICS RESEARCH UPDATE …………………………………………………… 11 DTx TREATMENT FOR CMT1A ……………………………………………………………………………….. 11 UNDER THE MICROSCOPE: ASOs ……………………………………………………………………….. 12 CMTA…
New Gene Therapy Development Program for CMT2A
…that it has licensed a sixth gene therapy development program under its research, collaboration and license agreement with the University of Pennsylvania and its Gene Therapy Program (GTP). The license…